Video

Evaluating dexamethasone intraocular suspension 9% post-cataract surgery

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|ASCRS

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Cathleen McCabe, MD, of The Eye Associates, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Read the article highlights: Study: Dexamethasone intraocular suspension 9% offering high surgeon, patient satisfaction after cataract surgery

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting
July 15th 2025

Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

A look at the vorolanib intravitreal insert compared with aflibercept for DME
July 8th 2025

A look at the vorolanib intravitreal insert compared with aflibercept for DME

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%
July 3rd 2025

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DR
June 28th 2025

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DR

© 2025 MJH Life Sciences

All rights reserved.